STAT

•

Kanaal • 2 programma’s

Nieuws

Nieuws

Tweewekelijks
Zakelijk

Zakelijk

Wekelijks bijgewerkt

31-05-2018

Episode 13: Spending millions on fatty liver disease. Overhyped cancer drugs. Who goes to BIO?

Is the drug industry spending millions on a made-up disease? Have the latest cancer drugs been overhyped? And why does anyone go to BIO?

31-05-2018

•

23 min
28-01-2021

Episode 145: Kevin Davies on the CRISPR boom, & Megan Ranney on scientific misinformation

First, we discuss the implications of Johnson & Johnson’s any-day-now data on a one-shot vaccine for Covid-19. Then, Kevin Davies, executive editor of the CRISPR Journal, joins us to talk about the strange boom in genome editing stocks and the future of the revolutionary technology. Finally, we talk to Megan Ranney, an emergency room physician and Brown University professor, about the challenges of Covid-19 science communication in a post-Trump world.

28-01-2021

•

34 min
15-06-2023

263: Biogen's messy board, Laronde's data problem, & the downside of a boom

Our colleague Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde Therapeutics, billed as “Moderna 2.0,” ran into behind-the-scenes problems with its scientific data. We also discuss how Biogen's boardroom scandal has roiled a company that was supposed to be entering a new era.

15-06-2023

•

40 min
04-08-2022

220: The last-minute push for drug pricing reform, Alnylam's success, and Sarepta's gamble

Is drug pricing reform really happening this time? Are things finally turning around for biotech? And is it ever wise to tweet your food? Rachel Cohrs, STAT's Washington correspondent, joins us to explain how congressional Democrats are on the verge of a coup in drug pricing — and what could still stand in their way. We also discuss the latest news in the life sciences, including some hotly anticipated data from Alnylam Pharmaceuticals, a $4 billion buyout deal, and other surprisingly good news for biotech.

04-08-2022

•

33 min
27-04-2023

256: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval

Andrew Joseph, STAT's Europe correspondent, joins us to explain the EU's sweeping proposal to overhaul how new drugs are regulated on the continent — and why the pharmaceutical industry is fighting it. We also discuss the latest news in the life sciences, including Lilly's surging business, a pair of new drug approvals, and a novel idea in Alzheimer's disease.

27-04-2023

•

29 min
10-12-2025

The revolution in dementia care is just beginning

When Jason Karlawish started working with dementia patients in the late ’90s, there often wasn’t much he could offer them. “I gave them a diagnosis,” he told me on this week’s episode of the “First Opinion Podcast,” but had limited medications to prescribe. Now Karlawish — who is STAT’s Neurotransmissions columnist; a professor of medicine, medical ethics, health policy, and neurology at the University of Pennsylvania; co-director of the Penn Memory Center; and executive producer of the “Age of Aging” podcast — says a revolution is taking place in dementia care, thanks to diagnostics that are removing uncertainty and treatments that actually have some effect.

10-12-2025

•

40 min
18-03-2021

Episode 152: Alison Buttenheim on Europe's vaccine scare, Lilly's Alzheimer's data, & a PR plea

First we unpack the crisis of confidence facing AstraZeneca's Covid-19 vaccine in Europe with Alison Buttenheim, a University Pennsylvania professor who studies vaccine acceptance. Then, we explain the latest data on an Alzheimer's disease treatment from Eli Lilly and why it has polarized experts in the field. Finally, we make a modest proposal to the biotech industry: Give honesty a chance.

18-03-2021

•

30 min
06-12-2023

93: Rep. Raul Ruiz on going from the emergency room to Congress

Before he joined Congress, Rep. Raul Ruiz, a Democrat from California, worked in another chaotic environment: the emergency department. Today, he says, he tries to bring his background in medicine and public health to policymaking. In particular, he has turned his attention to a shortage of infectious disease physicians that threatens U.S. preparedness for the next pandemic. Our conversation was based on his recent First Opinion essay, “The infectious disease doctor shortage threatens future pandemic preparedness.” Don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

06-12-2023

•

30 min
17-02-2021

Episode 2: Lauren Powell on the intersection of Covid-19 and racism

In June 2020, after George Floyd was killed by police in Minneapolis, Lauren Powell, who was then the executive director of Times Up Healthcare, wrote a searing essay for STAT's First Opinion. “My nightmare: Covid-19 meets racism meets the killing of a Black person by police." In this episode, Skerrett and Powell take a deep dive into that essay, talk about what it’s like coping with the Covid-19 pandemic in Richmond, Va., whether she took to the streets in the Black Lives Matter protests, and finding Black joy in the time of coronavirus.

17-02-2021

•

33 min
27-04-2022

52: A new hotline could save lives during mental health crises — if someone answers the phone

The roll out of a new mental health crisis line for the entire U.S., is scheduled to happen on July 16 — the blink of an eye in bureaucratic time. People in mental health crises or their family members will soon be able to dial 988, instead of 911 or the harder-to-remember 800-273-8255, the number for the National Suicide Prevention Lifeline. The thinking is that calls to 988 will route people to the care they need instead of to law enforcement or emergency personnel with limited training in working with people in the midst of mental health crises. This week on the "First Opinion Podcast," Benjamin Miller probes at some more concerns: Who will be answering the calls? And does the system have the capacity to take care of callers right away?

27-04-2022

•

31 min

Voices from the frontiers of health and medicine